Company Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides.
Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule.
The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006.
Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
| Country | United States |
| IPO Date | May 1, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Nadav Kidron Esq. |
Contact Details
Address: 1185 Avenue of the Americas New York, New York United States | |
| Website | https://www.oramed.com |
Stock Details
| Ticker Symbol | ORMP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001176309 |
| CUSIP Number | 68403P203 |
| ISIN Number | US68403P2039 |
| Employer ID | 98-0376008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nadav Kidron Esq. | President, Chief Executive Officer & Executive Chairman |
| Avraham Gabay | Chief Financial Officer, Treasurer & Secretary |
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer & Director |
| Joshua Hexter | Chief Operating & Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 03, 2025 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |
| Nov 08, 2024 | 4 | Filing |
| Nov 08, 2024 | 4 | Filing |
| Nov 08, 2024 | 4 | Filing |
| Nov 08, 2024 | 4 | Filing |